Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 4, 2010, Pages 448-457

  Du, Shouying ^a   Rashidi, Hooman H ^a,b   Le, Dzung T ^a   Kipps, Thomas J ^a   Broome, H Elizabeth ^a   Wang, Huan You ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Chronic lymphocytic leukemia; Systemic mastocytosis; Systemic mastocytosis with associated clonal haematological non mast cell lineage disease

Indexed keywords

ANTINEOPLASTIC AGENT; STEM CELL FACTOR RECEPTOR;

ARTICLE; CASE REPORT; CELL SEPARATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MASTOCYTOSIS; MIDDLE AGED; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SEPARATION; DNA MUTATIONAL ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MASTOCYTOSIS; MIDDLE AGED; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 77955857709     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Horny HP. Mastocytosis. An unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells. Am J Clin Pathol. 2009;132:438-447.
2. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escriibano L, and Valent P. Mastocytosis in WHO Classification of Tumors of the Haematopoietic and Lymphoid tissues. Swerdlow SH, Campo E, Harris NL, et al (Eds). LARC Press, Lyon, France, 2008.
3. Travis WD, Li CY, Yam LT, Bergstraih EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965-972.
4. Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal hematopoietic non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604-608.
5. Pardanani A, Lim KH, Lasho TL, Finke C, McClure RF, Li CY, and Tefferi A. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114:3769-3772.
6. Wilkins BS, Bucham SL, Webster J and Jones DB. Tryptase-positive mast cells accompany lymphocytic as well as lymphoplasmacytic lymphoma infiltrates in bone marrow trephine biopsies. Histopathol. 2001;39:150-155.
7. Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25:563-570.
8. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hemetopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366-2372.
9. Pardanani A, Reeder TL, Kimlinger TK, et al. Flt-3 and c-Kit mutations in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk Res. 2003;27:739-42.
10. Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological nonmast cells lineage disease associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010. DOI:10.1002/path.2677.
11. Gurish MF and Boyce JA. Mast cell growth, Differentiation, and Death. Clin Rew Allerg & Immunol. 2002;22:107-118.
12. Sotlar K, Saeger W, Stellmacher F, et al. "Occult" mastocytosis with activating c-Kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol. 2006;59:875-878.
13. Motwani P, Kocoglu M, lorsbach RB. Systemic mastocytosis in association with plasma cell dyscrasias: report of a case and review of the literature. Leuk Res. 2009;33:856-859.
14. Hagen W, Schwarzmeier J, Walchshofer S et al. A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol 1998; 76:167-74.
15. Stellmacher F, Sotlar K, Balleisen L, et al. Bone marrow mastocytosis associated with IgM kappa plasma cell myeloma. Leuk Lymphoma. 2004;45:801-805.
16. Pullarkat ST, Sedarat F, Paquette R, Said J. Systemic mastocytosis with plasma cell dyscrasia: report of a case. Leuk Res. 2008;32:1160-1163.
17. Sanz MA et al. Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica 2001;86:1106-1107.
18. Hauswirth AW, Fodinger M, Fritz M, Mullauer L, Simonitsch-Klupp I, Streubel B, Chott A, Sperr WS, Jager U, Valent P. Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lym phoproliferative disorder. Hum Pathol. 2008;39:917-924.
19. Ault P et al. Systemic mastocytosis in association with chronic lymphocytic leukemia: A rare diagnosis. Leuk Research. 2007;31:1755-1758.
20. Horny HP et al. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukemia (SM-CLL). J Clin Pathol. 2006;59:264-268
21. Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod Pathol. 2009;22:807-816.
22. Horny HP, Lange K, Sotlar K, and Valent P. Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol. 2003;56:575-578.
23. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's Macroglobulinemia support lymphoplasmacytic cell growth through CD154/ CD40 signaling. Ann Oncol 2006;17:1275-82.
24. Valent P, Akin C, Sperr WR, Mayerhofer M, Fodinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, and Metcalfe DD. Mastocytosis: pathology, genetics, and current option for therapy. Leuk Lymphoma 2005; 46:35-48
25. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84:790-794.
26. Santos DD, Hatjiharissi E, Tournilhac O, et al. CD52 expression on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006;6:478-483.